PitchSend

Investor Presentaiton

For personal use only Future research and innovation focus TELIX PHARMACEUTICALS TOT Targeted alpha therapy MTR1 + immuno-oncology Tumour microenvironment Artificial intelligence (AI) Radio-guided surgery "Next Generation" therapeutics with alpha-emitting radioisotopes MTR sets the "groundwork" for cancer immuno-therapy in combination Combining MTR with standard of care treatments for improved efficacy with biomarker-driven patient selection Tools to maximise clinical insights gained from imaging, link to therapeutic outcomes Bringing molecular imaging into the operating room (OR) 1. Molecularly targeted radiation Telix Pharmaceuticals Limited (ASX: TLX) 54 54

View entire presentation